Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends and variation in issuance of high-cost narcolepsy drugs by NHS England organisations and regions from 2019 to 2022.

Journal of sleep research·2024
Same author

Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer.

Breast cancer research and treatment·2024
Same author

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.

EBioMedicine·2022
Same author

Preventing late recurrence in hormone receptor-positive early breast cancer: a review.

European journal of cancer (Oxford, England : 1990)·2022
Same author

Positive role of continuous positive airway pressure for intensive care unit patients with severe hypoxaemic respiratory failure due to COVID-19 pneumonia: A single centre experience.

Journal of the Intensive Care Society·2022
Same author

Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.

Breast cancer research and treatment·2022
Same journal

Global prevalence of domestic violence against adults during COVID-19 and its determinants: A systematic review, meta-analysis, and meta-regression analysis.

Women's health (London, England)·2026
Same journal

Uncovering a hidden modulator for women in sports: An exploratory study of menstrual pain and brain connectivity.

Women's health (London, England)·2026
Same journal

"Comment on: "Commitment to inclusion: The importance of collaboration in gender equity work"".

Women's health (London, England)·2026
Same journal

Factors associated with unmet need for family planning among adolescent and young married women in Pakistan.

Women's health (London, England)·2026
Same journal

Recent obstetrical and gynaecological care experiences and their sociodemographic and mental health correlates: A latent class analysis.

Women's health (London, England)·2026
Same journal

Beyond gender and racial bias: Towards pro-justice ethical GenAI use in medicine and health.

Women's health (London, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Trastuzumab.

Ian E Smith1, Susan G Cross

  • 1Breast Unit, Department of Medicine, The Royal Marsden Hospital, Fulham Road,London, SW3 6JJ, UK. ian.smith@rmh.nthames.nhs.uk.

Women'S Health (London, England)
|October 7, 2009
PubMed
Summary
This summary is machine-generated.

Human epidermal growth factor receptor 2 (HER2) is overexpressed in aggressive breast cancers. Trastuzumab, a targeted therapy, shows effectiveness in treating metastatic, neoadjuvant, and adjuvant breast cancer.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Related Experiment Videos

Last Updated: Jun 19, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Breast cancer exhibits significant heterogeneity with diverse clinical and biological subtypes.
  • Human epidermal growth factor receptor 2 (HER2) overexpression occurs in about 20% of breast cancers, often linked to gene amplification.
  • HER2 overexpression typically signifies a more aggressive tumor type and a poorer prognosis.

Purpose of the Study:

  • To review the role and efficacy of trastuzumab in breast cancer treatment.
  • To highlight trastuzumab's targeted action against HER2-overexpressing breast cancer cells.

Main Methods:

  • Review of clinical trials and published data on trastuzumab therapy.
  • Analysis of trastuzumab's effectiveness as a single agent and in combination therapies.
  • Evaluation of trastuzumab's application in metastatic, neoadjuvant, and adjuvant settings.

Main Results:

  • Trastuzumab is an effective humanized monoclonal antibody targeting HER2.
  • Demonstrated activity in metastatic breast cancer, both alone and with chemotherapy.
  • Recent studies show benefits in neoadjuvant and adjuvant breast cancer treatment.

Conclusions:

  • Trastuzumab is a key therapeutic agent for HER2-positive breast cancer.
  • Its efficacy spans various stages of breast cancer, improving patient outcomes.
  • Targeted therapy against HER2 represents a significant advancement in breast cancer treatment.